{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:42:32Z","timestamp":1791052952970,"version":"4.1.0"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T00:00:00Z","timestamp":1606867200000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hyperactive signaling of the Janus-Associated Kinase\/Signal Transducers and Activators of Transcription (JAK\/STAT) pathway is central to the pathogenesis of Philadelphia-chromosome-negative myeloproliferative neoplasms (MPN), i.e., polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) which are characterized by inherent biological and clinical heterogeneity. Patients with MPNs suffer from substantial symptom burden and curtailed longevity due to thrombohemorrhagic complications or progression to myelofibrosis or acute myeloid leukemia. Therefore, the management strategies focus on thrombosis risk mitigation in PV\/ET, alleviation of symptom burden and improvement in cytopenias and red blood cell transfusion requirements, and disease course alteration in PMF. The United States Food and Drug Administration\u2019s (USFDA) approval of two JAK inhibitors (ruxolitinib, fedratinib) has transformed the therapeutic landscape of MPNs in assuaging the need for frequent therapeutic phlebotomy (PV) and reduction in spleen and symptom burden (PV and PMF). Despite improving biological understanding of these complex clonal hematopoietic stem\/progenitor cell neoplasms, none of the currently available therapies appear to modify the proclivity of the disease per se, thereby remaining an urgent unmet clinical need and an ongoing area of intense clinical investigation. This review will highlight the evolving targeted therapeutic agents that are in early- and late-stage MPN clinical development.<\/jats:p>","DOI":"10.1186\/s13045-020-00995-y","type":"journal-article","created":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T11:03:45Z","timestamp":1606907025000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Novel therapeutics in myeloproliferative neoplasms"],"prefix":"10.1186","volume":"13","author":[{"given":"Sangeetha","family":"Venugopal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8400-0483","authenticated-orcid":false,"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,2]]},"reference":[{"issue":"22","key":"995_CR1","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1056\/NEJMra1406186","volume":"376","author":"JL Spivak","year":"2017","unstructured":"Spivak JL. Myeloproliferative neoplasms. N Engl J Med. 2017;376(22):2168\u201381.","journal-title":"N Engl J Med"},{"issue":"4","key":"995_CR2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387\u201397.","journal-title":"Cancer Cell"},{"issue":"25","key":"995_CR3","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391\u2013405.","journal-title":"N Engl J Med"},{"issue":"7","key":"995_CR4","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270.","journal-title":"PLoS Med"},{"issue":"2","key":"995_CR5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s13148-011-0050-6","volume":"2","author":"J Mascarenhas","year":"2011","unstructured":"Mascarenhas J, Roper N, Chaurasia P, Hoffman R. Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies. Clinical epigenetics. 2011;2(2):197\u2013212. https:\/\/doi.org\/10.1007\/s13148-011-0050-6.","journal-title":"Clinical epigenetics"},{"issue":"9","key":"995_CR6","doi-asserted-by":"publisher","first-page":"656","DOI":"10.7326\/0003-4819-123-9-199511010-00003","volume":"123","author":"GIS Policitemia","year":"1995","unstructured":"Policitemia GIS. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med. 1995;123(9):656\u201364.","journal-title":"Ann Intern Med"},{"issue":"3","key":"995_CR7","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3324\/haematol.12053","volume":"93","author":"V De Stefano","year":"2008","unstructured":"De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica. 2008;93(3):372\u201380.","journal-title":"Haematologica"},{"key":"995_CR8","volume-title":"Risk of arterial and venous thrombosis in 11,155 patients with myeloproliferative neoplasms and 44,620 matched controls; a population-based study","author":"M Hultcrantz","year":"2014","unstructured":"Hultcrantz M, Andersson TM, Landgren O, Derolf AR, Dickman PW, Bj\u00f6rkholm M, et al. Risk of arterial and venous thrombosis in 11,155 patients with myeloproliferative neoplasms and 44,620 matched controls; a population-based study. Washington, DC: American Society of Hematology; 2014."},{"issue":"14","key":"995_CR9","first-page":"2725","volume":"121","author":"JA Kennedy","year":"2013","unstructured":"Kennedy JA, Atenafu EG, Messner HA, Craddock KJ, Brandwein JM, Lipton JH, et al. Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms. Blood J Am Soc Hematol. 2013;121(14):2725\u201333.","journal-title":"Blood J Am Soc Hematol"},{"issue":"9","key":"995_CR10","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/leu.2013.163","volume":"27","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi A, Rodeghiero F, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874\u201381.","journal-title":"Leukemia"},{"issue":"26","key":"995_CR11","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","volume":"120","author":"T Barbui","year":"2012","unstructured":"Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120(26):5128\u201333.","journal-title":"Blood"},{"issue":"1","key":"995_CR12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1182\/bloodadvances.2018026658","volume":"3","author":"H Ali","year":"2019","unstructured":"Ali H, Aldoss I, Yang D, Mokhtari S, Khaled S, Aribi A, et al. MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu\/Mel conditioning regimen. Blood Adv. 2019;3(1):83\u201395.","journal-title":"Blood Adv"},{"issue":"19","key":"995_CR13","first-page":"3021","volume":"124","author":"T Barbui","year":"2014","unstructured":"Barbui T, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Rodeghiero F, et al. In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood J Am Soc Hematol. 2014;124(19):3021\u20133.","journal-title":"Blood J Am Soc Hematol"},{"issue":"1","key":"995_CR14","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1208500","volume":"368","author":"R Marchioli","year":"2013","unstructured":"Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22\u201333.","journal-title":"N Engl J Med"},{"issue":"10","key":"995_CR15","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1182\/blood-2012-10-429134","volume":"121","author":"C Patrono","year":"2013","unstructured":"Patrono C, Rocca B, De Stefano V. Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. Blood. 2013;121(10):1701\u201311.","journal-title":"Blood"},{"issue":"1","key":"995_CR16","first-page":"17","volume":"34","author":"SM Fruchtman","year":"1997","unstructured":"Fruchtman SM, Mack K, Kaplan ME, Peterson P, Berk PD, Wasserman LR. From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol. 1997;34(1):17\u201323.","journal-title":"Semin Hematol"},{"issue":"17","key":"995_CR17","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","volume":"332","author":"S Cortelazzo","year":"1995","unstructured":"Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995;332(17):1132\u20136.","journal-title":"N Engl J Med"},{"issue":"8","key":"995_CR18","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","volume":"112","author":"JJ Kiladjian","year":"2008","unstructured":"Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112(8):3065\u201372.","journal-title":"Blood"},{"issue":"24","key":"995_CR19","first-page":"2585","volume":"126","author":"E Verger","year":"2015","unstructured":"Verger E, Cassinat B, Chauveau A, Dosquet C, Giraudier S, Schlageter M-H, et al. Clinical and molecular response to interferon-\u03b1 therapy in essential thrombocythemia patients with CALR mutations. Blood J Am Soc Hematol. 2015;126(24):2585\u201391.","journal-title":"Blood J Am Soc Hematol"},{"issue":"5","key":"995_CR20","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426\u201335.","journal-title":"N Engl J Med"},{"issue":"1","key":"995_CR21","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","volume":"18","author":"F Passamonti","year":"2017","unstructured":"Passamonti F, Griesshammer M, Palandri F, Egyed M, Benevolo G, Devos T, et al. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncol. 2017;18(1):88\u201399.","journal-title":"Lancet Oncol"},{"issue":"2","key":"995_CR22","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/blood-2015-10-676742","volume":"128","author":"C Casu","year":"2016","unstructured":"Casu C, Oikonomidou PR, Chen H, Nandi V, Ginzburg Y, Prasad P, et al. Minihepcidin peptides as disease modifiers in mice affected by beta-thalassemia and polycythemia vera. Blood. 2016;128(2):265\u201376.","journal-title":"Blood"},{"issue":"10","key":"995_CR23","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.exphem.2015.05.013","volume":"43","author":"KY King","year":"2015","unstructured":"King KY, Matatall KA, Shen C-C, Goodell MA, Swierczek SI, Prchal JT. Comparative long-term effects of interferon \u03b1 and hydroxyurea on human hematopoietic progenitor cells. Exp Hematol. 2015;43(10):912\u20138.","journal-title":"Exp Hematol"},{"issue":"6","key":"995_CR24","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1182\/blood-2006-03-009860","volume":"108","author":"J-J Kiladjian","year":"2006","unstructured":"Kiladjian J-J, Cassinat B, Turlure P, Cambier N, Roussel M, Bellucci S, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon \u03b1\u20132a. Blood. 2006;108(6):2037\u201340.","journal-title":"Blood"},{"issue":"32","key":"995_CR25","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","volume":"27","author":"A Quint\u00e1s-Cardama","year":"2009","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009;27(32):5418.","journal-title":"J Clin Oncol"},{"issue":"18","key":"995_CR26","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1182\/blood.2019000428","volume":"134","author":"A Yacoub","year":"2019","unstructured":"Yacoub A, Mascarenhas J, Kosiorek H, Prchal JT, Berenzon D, Baer MR, et al. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood. 2019;134(18):1498\u2013509.","journal-title":"Blood"},{"issue":"4","key":"995_CR27","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/ajh.23928","volume":"90","author":"NC Them","year":"2015","unstructured":"Them NC, Bagienski K, Berg T, Gisslinger B, Schalling M, Chen D, et al. Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. Am J Hematol. 2015;90(4):288\u201394.","journal-title":"Am J Hematol"},{"issue":"15","key":"995_CR28","first-page":"1762","volume":"126","author":"H Gisslinger","year":"2015","unstructured":"Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, et al. Ropeginterferon alfa-2b, a novel IFN\u03b1-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood J Am Soc Hematol. 2015;126(15):1762\u20139.","journal-title":"Blood J Am Soc Hematol"},{"key":"995_CR29","unstructured":"Tiziano Barbui AMV, Valerio De Stefano, Arianna M, Alessandra C, Arianna G, Fabio C, Massimiliano B, Alessandra I, Francesca P, Giulia B, Fabrizio P, Alessandra R, Giuseppe C, Marianna C, Davide R, Caterina M, Sergio S, Elisa R, Andrea P, Nicola C, Barbara M, Emma C, Giuseppe GL, Paola G, Elena R, Silvia B, Francesca L, Luigi S, Cristina B, Nicola V, Marta B, Alessandro R. Phase II Randomized clinical trial comparing ropeginterferon versus phlebotomy in low-risk patients with polycythemia Vera. Results of the Pre-planned Interim Analysis. EHA. EHA Library. Barbui T. 06\/14\/20; 303391; LB26022020."},{"issue":"Supplement 1","key":"995_CR30","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1182\/blood-2018-99-111946","volume":"132","author":"J Mascarenhas","year":"2018","unstructured":"Mascarenhas J, Kosiorek HE, Prchal JT, Rambaldi A, Berenzon D, Yacoub A, et al. Results of the myeloproliferative neoplasms-research consortium (MPN-RC) 112 randomized trial of pegylated interferon alfa-2a (PEG) versus hydroxyurea (HU) therapy for the treatment of high risk polycythemia vera (PV) and high risk essential thrombocythemia (ET). Blood. 2018;132(Supplement 1):577.","journal-title":"Blood"},{"issue":"3","key":"995_CR31","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","volume":"7","author":"H Gisslinger","year":"2020","unstructured":"Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7(3):e196\u2013208.","journal-title":"Lancet Haematol"},{"issue":"4","key":"995_CR32","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/sj.leu.2405049","volume":"22","author":"V Guerini","year":"2008","unstructured":"Guerini V, Barbui V, Spinelli O, Salvi A, Dellacasa C, Carobbio A, et al. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F. Leukemia. 2008;22(4):740\u20137.","journal-title":"Leukemia"},{"issue":"4","key":"995_CR33","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1365-2141.2010.08266.x","volume":"150","author":"A Rambaldi","year":"2010","unstructured":"Rambaldi A, Dellacasa CM, Finazzi G, Carobbio A, Ferrari ML, Guglielmelli P, et al. A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol. 2010;150(4):446\u201355.","journal-title":"Br J Haematol"},{"issue":"5","key":"995_CR34","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/bjh.12332","volume":"161","author":"G Finazzi","year":"2013","unstructured":"Finazzi G, Vannucchi AM, Martinelli V, Ruggeri M, Nobile F, Specchia G, et al. A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. Br J Haematol. 2013;161(5):688\u201394.","journal-title":"Br J Haematol"},{"issue":"8","key":"995_CR35","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1038\/s41375-020-0735-y","volume":"34","author":"A Rambaldi","year":"2020","unstructured":"Rambaldi A, Iurlo A, Vannucchi AM, Noble R, von Bubnoff N, Guarini A, et al. Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib\/II study. Leukemia. 2020;34(8):2234\u20137.","journal-title":"Leukemia"},{"issue":"5","key":"995_CR36","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1182\/blood-2013-11-536854","volume":"124","author":"M Lu","year":"2014","unstructured":"Lu M, Xia L, Li Y, Wang X, Hoffman R. The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon \u03b1 2a target JAK2V617F-positive progenitor and stem cells. Blood. 2014;124(5):771\u20139.","journal-title":"Blood"},{"issue":"6","key":"995_CR37","first-page":"525","volume":"134","author":"J Mascarenhas","year":"2019","unstructured":"Mascarenhas J, Lu M, Kosiorek H, Virtgaym E, Xia L, Sandy L, et al. Oral idasanutlin in patients with polycythemia vera. Blood J Am Soc Hematol. 2019;134(6):525\u201333.","journal-title":"Blood J Am Soc Hematol"},{"issue":"1","key":"995_CR38","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1182\/blood-2014-04-569525","volume":"124","author":"D Niebel","year":"2014","unstructured":"Niebel D, Kirfel J, Janzen V, H\u00f6ller T, Majores M, G\u00fctgemann I. Lysine-specific demethylase 1 (LSD1) in hematopoietic and lymphoid neoplasms. Blood. 2014;124(1):151\u20132.","journal-title":"Blood"},{"issue":"3","key":"995_CR39","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1097\/HS9.0000000000000054","volume":"2","author":"JS Jutzi","year":"2018","unstructured":"Jutzi JS, Kleppe M, Dias J, Staehle HF, Shank K, Teruya-Feldstein J, et al. LSD1 inhibition prolongs survival in mouse models of MPN by selectively targeting the disease clone. HemaSphere. 2018;2(3):e54.","journal-title":"HemaSphere"},{"issue":"25","key":"995_CR40","first-page":"3253","volume":"127","author":"AP Theocharides","year":"2016","unstructured":"Theocharides AP, Lundberg P, Lakkaraju AK, Lysenko V, Myburgh R, Aguzzi A, et al. Homozygous calreticulin mutations in patients with myelofibrosis lead to acquired myeloperoxidase deficiency. Blood J Am Soc Hematol. 2016;127(25):3253\u20139.","journal-title":"Blood J Am Soc Hematol"},{"issue":"4","key":"995_CR41","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1158\/2159-8290.CD-15-1434","volume":"6","author":"S Elf","year":"2016","unstructured":"Elf S, Abdelfattah NS, Chen E, Perales-Pat\u00f3n J, Rosen EA, Ko A, et al. Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation. Cancer Discov. 2016;6(4):368\u201381.","journal-title":"Cancer Discov"},{"issue":"2","key":"995_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-018-0166-4","volume":"9","author":"MO Holmstr\u00f6m","year":"2019","unstructured":"Holmstr\u00f6m MO, Ahmad SM, Klausen U, Bendtsen SK, Martinenaite E, Riley CH, et al. High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals. Blood Cancer J. 2019;9(2):1\u201314.","journal-title":"Blood Cancer J"},{"issue":"2","key":"995_CR43","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/leu.2017.214","volume":"32","author":"M Holmstr\u00f6m","year":"2018","unstructured":"Holmstr\u00f6m M, Martinenaite E, Ahmad S, Met \u00d6, Friese C, Kjaer L, et al. The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy. Leukemia. 2018;32(2):429\u201337.","journal-title":"Leukemia"},{"issue":"9","key":"995_CR44","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1158\/2159-8290.CD-18-1356","volume":"9","author":"C Cimen Bozkus","year":"2019","unstructured":"Cimen Bozkus C, Roudko V, Finnigan JP, Mascarenhas J, Hoffman R, Iancu-Rubin C, et al. Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T-cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms. Cancer Discov. 2019;9(9):1192\u2013207.","journal-title":"Cancer Discov"},{"issue":"9","key":"995_CR45","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799\u2013807.","journal-title":"N Engl J Med"},{"issue":"7","key":"995_CR46","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","volume":"4","author":"CN Harrison","year":"2017","unstructured":"Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu RV, Zachee P, et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol. 2017;4(7):e317\u201324.","journal-title":"Lancet Haematol"},{"issue":"9","key":"995_CR47","first-page":"1125","volume":"130","author":"KJ Newberry","year":"2017","unstructured":"Newberry KJ, Patel K, Masarova L, Luthra R, Manshouri T, Jabbour E, et al. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood J Am Soc Hematol. 2017;130(9):1125\u201331.","journal-title":"Blood J Am Soc Hematol"},{"issue":"1","key":"995_CR48","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13045-017-0527-7","volume":"10","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, Gotlib J, Mesa RA, Vannucchi AM, Kiladjian J-J, Cervantes F, et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol. 2017;10(1):156.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"995_CR49","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00277-017-3194-4","volume":"97","author":"AT Kuykendall","year":"2018","unstructured":"Kuykendall AT, Shah S, Talati C, Al Ali N, Sweet K, Padron E, et al. Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. Ann Hematol. 2018;97(3):435\u201341.","journal-title":"Ann Hematol"},{"issue":"5","key":"995_CR50","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","volume":"4","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Vannucchi AM, Mead A, Egyed M, Szoke A, Suvorov A, et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematol. 2017;4(5):e225\u201336.","journal-title":"Lancet Haematol"},{"issue":"5","key":"995_CR51","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","volume":"4","author":"J Mascarenhas","year":"2018","unstructured":"Mascarenhas J, Hoffman R, Talpaz M, et al. Pacritinib vs. best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial. JAMA Oncol. 2018;4(5):652\u20139.","journal-title":"JAMA Oncol"},{"issue":"1","key":"995_CR52","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1182\/blood-2019-129293","volume":"134","author":"AT Gerds","year":"2019","unstructured":"Gerds AT, Savona MR, Scott BL, Talpaz M, Egyed M, Harrison CN, et al. Results of PAC203: a randomized phase 2 dose-finding study and determination of the recommended dose of pacritinib. Blood. 2019;134(1):667.","journal-title":"Blood"},{"key":"995_CR53","doi-asserted-by":"crossref","unstructured":"Harrison CN, Gerds AT, Kiladjian J-J, D\u00f6hner K, Buckley SA, Smith JA, et al. Pacifica: a randomized, controlled phase 3 study of pacritinib vs. Physician's choice in patients with primary myelofibrosis, post polycythemia vera myelofibrosis, or post essential thrombocytopenia myelofibrosis with severe thrombocytopenia (platelet count <50,000\/mL). Blood 2019;134(Supplement_1):4175.","DOI":"10.1182\/blood-2019-129245"},{"issue":"2","key":"995_CR54","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3324\/haematol.2016.151126","volume":"102","author":"JO Mascarenhas","year":"2017","unstructured":"Mascarenhas JO, Talpaz M, Gupta V, Foltz LM, Savona MR, Paquette R, et al. Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. Haematologica. 2017;102(2):327\u201335.","journal-title":"Haematologica"},{"issue":"16","key":"995_CR55","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1182\/blood-2018-04-846626","volume":"132","author":"L Masarova","year":"2018","unstructured":"Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, et al. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018;132(16):1664\u201374.","journal-title":"Blood"},{"key":"995_CR56","unstructured":"Mascarenhas J, Ch AP, Td FPRR, et al. CPI-0610, a bromodomain and extraterminal domain protein (BET) inhibitor, in combination with ruxolitinib. In JAK inhibitor treatment na\u00efve myelofibrosis patients: update from manifest phase 2 study. EHA25; Virtual2020."},{"key":"995_CR57","unstructured":"Verstovsek S, JM, MK, RH, RR, VG, et al. CPI-0610, Bromodomain and extraterminal domain protein (BET) inhibitor, as 'add-on' to ruxolitinib (RUX). In: Advanced myelofibrosis patients with suboptimal response: update of manifest phase 2 study. EHA25; Virtual2020."},{"key":"995_CR58","unstructured":"Moyo T, JP, YH, OO, SM, RC, et al. Resurrecting response to ruxolitinib: a phase I study testing the combination of ruxolitinib and the PI3K delta inhibitor umbralisib in ruxolitinib-experienced myelofibrosis. EHA2018."},{"key":"995_CR59","unstructured":"Yacoub A, ESW, RKR, UB, MK, HA, et al. Addition of parsaclisib, a PI3KDELTA inhibitor. In: Patients (PTS) with suboptimal response to ruxolitinib (RUX): a phase 2 study in PTS with myelofibrosis (MF). EHA 6\/12\/202020."},{"issue":"Supplement_1","key":"995_CR60","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1182\/blood-2019-130158","volume":"134","author":"CN Harrison","year":"2019","unstructured":"Harrison CN, Garcia JS, Mesa RA, Somervaille TC, Komrokji RS, Pemmaraju N, et al. Results from a phase 2 study of navitoclax in combination with ruxolitinib in patients with primary or secondary myelofibrosis. Blood. 2019;134(Supplement_1):671.","journal-title":"Blood"},{"issue":"Supplement_1","key":"995_CR61","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1182\/blood-2018-99-110785","volume":"132","author":"J-J Kiladjian","year":"2018","unstructured":"Kiladjian J-J, Soret-Dulphy J, Resche-Rigon M, Boyer-Perrard F, Barraco F, Rolland-Neyret V, et al. Ruxopeg, a multi-center bayesian phase 1\/2 adaptive randomized trial of the combination of ruxolitinib and pegylated interferon alpha 2a in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis. Blood. 2018;132(Supplement_1):581.","journal-title":"Blood"},{"issue":"1","key":"995_CR62","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","volume":"10","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, et al. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. 2017;10(1):55.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"995_CR63","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","volume":"122","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013;122(8):1395\u20138.","journal-title":"Blood"},{"issue":"7","key":"995_CR64","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1080\/13696998.2020.1741381","volume":"23","author":"J Mascarenhas","year":"2020","unstructured":"Mascarenhas J, Mehra M, He J, Potluri R, Loefgren C. Patient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis. J Med Econ. 2020;23(7):721\u20137.","journal-title":"J Med Econ"},{"issue":"6","key":"995_CR65","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/ajh.25777","volume":"95","author":"CN Harrison","year":"2020","unstructured":"Harrison CN, Schaap N, Vannucchi AM, Kiladjian J-J, Jourdan E, Silver RT, et al. Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: an updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. Am J Hematol. 2020;95(6):594\u2013603.","journal-title":"Am J Hematol"},{"issue":"13","key":"995_CR66","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1182\/blood-2016-09-740092","volume":"129","author":"M Asshoff","year":"2017","unstructured":"Asshoff M, Petzer V, Warr MR, Haschka D, Tymoszuk P, Demetz E, et al. Momelotinib inhibits ACVR1\/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents. Blood. 2017;129(13):1823\u201330.","journal-title":"Blood"},{"issue":"34","key":"995_CR67","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","volume":"35","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, et al. SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-Na\u00efve patients with myelofibrosis. J Clin Oncol. 2017;35(34):3844\u201350.","journal-title":"J Clin Oncol"},{"issue":"2","key":"995_CR68","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","volume":"5","author":"CN Harrison","year":"2018","unstructured":"Harrison CN, Vannucchi AM, Platzbecker U, Cervantes F, Gupta V, Lavie D, et al. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol. 2018;5(2):e73\u201381.","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"995_CR69","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1182\/blood-2018-99-111349","volume":"132","author":"ST Oh","year":"2018","unstructured":"Oh ST, Talpaz M, Gerds AT, Gupta V, Verstovsek S, Mesa RA, et al. Hepcidin suppression by momelotinib is associated with increased iron availability and erythropoiesis in transfusion-dependent myelofibrosis patients. Blood. 2018;132(Supplement 1):4282.","journal-title":"Blood"},{"issue":"9","key":"995_CR70","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1084\/jem.20160283","volume":"213","author":"S Verstovsek","year":"2016","unstructured":"Verstovsek S, Manshouri T, Pilling D, Bueso-Ramos CE, Newberry KJ, Prijic S, et al. Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. J Exp Med. 2016;213(9):1723\u201340.","journal-title":"J Exp Med"},{"issue":"Supplement 1","key":"995_CR71","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1182\/blood-2018-99-115362","volume":"132","author":"S Verstovsek","year":"2018","unstructured":"Verstovsek S, Hasserjian RP, Pozdnyakova O, Veletic I, Mesa RA, Foltz L, et al. PRM-151 in myelofibrosis: efficacy and safety in an open label extension study. Blood. 2018;132(Supplement 1):686.","journal-title":"Blood"},{"key":"995_CR72","doi-asserted-by":"crossref","unstructured":"Verstovsek S, MT, MW, JP, AI, PtB, et al. A randomized, double blind phase 2 study of 3 different doses of PRM-151 in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib. EHA242019.","DOI":"10.1097\/01.HS9.0000561592.51072.9b"},{"issue":"Supplement_1","key":"995_CR73","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1182\/blood-2019-123244","volume":"134","author":"K Pettit","year":"2019","unstructured":"Pettit K, Gerds AT, Yacoub A, Watts JM, Tartaczuch M, Bradley TJ, et al. A phase 2a study of the LSD1 inhibitor img-7289 (bomedemstat) for the treatment of myelofibrosis. Blood. 2019;134(Supplement_1):556.","journal-title":"Blood"},{"issue":"Supplement_1","key":"995_CR74","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1182\/blood-2019-123836","volume":"134","author":"R Garcia-Delgado","year":"2019","unstructured":"Garcia-Delgado R, McLornan DP, Rejt\u0151 L, Jourdan E, Al-Ali HK, Pluta A, et al. An open-label, phase 2 study of KRT-232, a first-in-class, oral small molecule inhibitor of MDM2, for the treatment of patients with myelofibrosis (mf) who have previously received treatment with a JAK inhibitor. Blood. 2019;134(Supplement_1):2945.","journal-title":"Blood"},{"key":"995_CR75","unstructured":"Al-Ali HK, RGD, AL, AP, DPM, PV, et al. KRT\u2011232, A first-in-class, murine double minute 2 inhibitor (MDM2I), for myelofibrosis (MF) relapsed or refractory (R\/R) to Janus-associated kinase inhibitor (JAKI) Treatment (TX); 2020."},{"issue":"Supplement_1","key":"995_CR76","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1182\/blood-2019-130046","volume":"134","author":"N Pemmaraju","year":"2019","unstructured":"Pemmaraju N, Carter BZ, Kantarjian HM, Cortes JE, Bose P, Kadia TM, et al. Final results of phase 2 clinical trial of LCL161, a novel oral SMAC mimetic\/IAP antagonist, for patients with intermediate to high risk myelofibrosis. Blood. 2019;134(Supplement_1):555.","journal-title":"Blood"},{"issue":"16","key":"995_CR77","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1158\/1078-0432.CCR-19-1005","volume":"25","author":"N Gangat","year":"2019","unstructured":"Gangat N, Marinaccio C, Swords R, Watts JM, Gurbuxani S, Rademaker A, Fought AJ, Frankfurt O, Altman JK, Wen QJ, Farnoud N, Famulare CA, Patel A, Tapia R, Vallapureddy RR, Barath S, Graf A, Handlogten A, Zblewski D, Patnaik MM, Al-kali A, Dinh YT, Prahl KE, Patel S, Nobrega JC, Tejera D, Thomassen A, Gao J, Ji P, Rampal RK, Giles FJ, Tefferi A, Stein B, Crispino JD. Aurora kinase a inhibition provides clinical benefit, normalizes megakaryocytes, and reduces bone marrow fibrosis in patients with myelofibrosis: a phase I trial. Clin Cancer Res. 2019;25(16):4898\u2013906.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"995_CR78","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","volume":"380","author":"N Pemmaraju","year":"2019","unstructured":"Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Madeleine Duvic J, Sloan M, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019;380(17):1628\u201337.","journal-title":"N Engl J Med"},{"issue":"Supplement_1","key":"995_CR79","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1182\/blood-2019-131217","volume":"134","author":"N Pemmaraju","year":"2019","unstructured":"Pemmaraju N, Gupta V, Ali H, Yacoub A, Wang ES, Lee S, et al. Results from a phase 1\/2 clinical trial of tagraxofusp (SL-401) in patients with intermediate, or high risk, relapsed\/refractory myelofibrosis. Blood. 2019;134(Supplement_1):558.","journal-title":"Blood"},{"key":"995_CR80","doi-asserted-by":"publisher","first-page":"e366","DOI":"10.1038\/bcj.2015.95","volume":"5","author":"S Cerquozzi","year":"2015","unstructured":"Cerquozzi S, Tefferi A. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J. 2015;5:e366.","journal-title":"Blood Cancer J"},{"issue":"Supplement_1","key":"995_CR81","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1182\/blood-2018-99-115163","volume":"132","author":"J Mascarenhas","year":"2018","unstructured":"Mascarenhas J, Komrokji RS, Cavo M, Martino B, Niederwieser D, Reiter A, et al. Imetelstat Is effective treatment for patients with intermediate-2 or high-risk myelofibrosis who have relapsed on or are refractory to janus kinase inhibitor therapy: results of a phase 2 randomized study of two dose levels. Blood. 2018;132(Supplement_1):685.","journal-title":"Blood"},{"key":"995_CR82","unstructured":"Mascarenhas J, RSK, BM, DN, AR, BLS, et al. Telomerase activity, telomere length and htert expression correlate with clinical outcomes in higher-risk myelofibrosis (MF) relapsed\/refractory (R\/R) to Janus kinase inhibitor treated with Imetelstat; 2020."},{"issue":"S1","key":"995_CR83","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1097\/01.HS9.0000564088.98639.88","volume":"3","author":"A Kuykendall","year":"2019","unstructured":"Kuykendall A, Wan Y, Mascarenhas J, Kiladjian J-J, Vannucchi A, Wang J, et al. PS1456 favorable overall survival of imetelstat-treated relapsed\/refractory myelofibrosis patients compared with closely matched real world data. HemaSphere. 2019;3(S1):669\u201370.","journal-title":"HemaSphere"},{"issue":"12","key":"995_CR84","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/s41408-017-0032-9","volume":"7","author":"A Tefferi","year":"2017","unstructured":"Tefferi A. Anemia in myelofibrosis\u2014prevalence, the U2AF1 connection, new treatments. Blood Cancer J. 2017;7(12):648.","journal-title":"Blood Cancer J"},{"issue":"S1","key":"995_CR85","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1097\/01.HS9.0000564680.75954.af","volume":"3","author":"F Stegelmann","year":"2019","unstructured":"Stegelmann F, Koschmieder S, Isfort S, Hochhaus A, Heidel F, Hebart H, et al. S1608 Ruxolitinib plus pomalidomide in myelofibrosis with Anemia: results from the MPNSG-0212 combination trial (NCT01644110). HemaSphere. 2019;3(S1):740\u20131.","journal-title":"HemaSphere"},{"issue":"2","key":"995_CR86","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.exphem.2012.12.002","volume":"41","author":"C Iancu-Rubin","year":"2013","unstructured":"Iancu-Rubin C, Mosoyan G, Wang J, Kraus T, Sung V, Hoffman R. Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap. Exp Hematol. 2013;41(2):155\u201366.","journal-title":"Exp Hematol"},{"issue":"6","key":"995_CR87","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1111\/bjh.12838","volume":"165","author":"S Carrancio","year":"2014","unstructured":"Carrancio S, Markovics J, Wong P, Leisten J, Castiglioni P, Groza MC, et al. An activin receptor II A ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin. Br J Haematol. 2014;165(6):870\u201382.","journal-title":"Br J Haematol"},{"issue":"2","key":"995_CR88","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa1908892","volume":"382","author":"P Fenaux","year":"2020","unstructured":"Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med. 2020;382(2):140\u201351.","journal-title":"N Engl J Med"},{"issue":"Supplement_1","key":"995_CR89","first-page":"255","volume":"130","author":"P Bose","year":"2017","unstructured":"Bose P, Daver N, Pemmaraju N, Jabbour EJ, Estrov Z, Pike A, et al. Sotatercept (ACE-011) alone and in combination with ruxolitinib in patients (pts) with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF) and anemia. Blood. 2017;130(Supplement_1):255.","journal-title":"Blood"},{"issue":"Supplement_1","key":"995_CR90","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1182\/blood-2019-122546","volume":"134","author":"AT Gerds","year":"2019","unstructured":"Gerds AT, Vannucchi AM, Passamonti F, Kremyanskaya M, Gotlib JR, Palmer JM, et al. A phase 2 study of luspatercept in patients with myelofibrosis-associated anemia. Blood. 2019;134(Supplement_1):557.","journal-title":"Blood"},{"issue":"7","key":"995_CR91","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1182\/blood-2002-09-2928","volume":"101","author":"RA Mesa","year":"2003","unstructured":"Mesa RA, Steensma DP, Pardanani A, Li CY, Elliott M, Kaufmann SH, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood. 2003;101(7):2534\u201341.","journal-title":"Blood"},{"issue":"Supplement_1","key":"995_CR92","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1182\/blood-2019-127661","volume":"134","author":"RK Rampal","year":"2019","unstructured":"Rampal RK, Verstovsek S, Devlin SM, King AC, Stein EM, Pemmaraju N, et al. Safety and efficacy of combined ruxolitinib and thalidomide in patients with myelofibrosis: a phase II study. Blood. 2019;134(Supplement_1):4163.","journal-title":"Blood"},{"issue":"22","key":"995_CR93","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1182\/blood.V128.22.634.634","volume":"128","author":"RK Rampal","year":"2016","unstructured":"Rampal RK, Maria P-O, Amritha Varshini HS, Levine RL, Cao A. Synergistic therapeutic efficacy of combined JAK1\/2, Pan-PIM, and CDK4\/6 inhibition in myeloproliferative neoplasms. Blood. 2016;128(22):634.","journal-title":"Blood"},{"issue":"2","key":"995_CR94","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1172\/JCI94516","volume":"128","author":"AS McKenney","year":"2018","unstructured":"McKenney AS, Lau AN, Somasundara AVH, Spitzer B, Intlekofer AM, Ahn J, et al. JAK2\/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition. J Clin Invest. 2018;128(2):789\u2013804.","journal-title":"J Clin Invest"},{"issue":"Supplement_1","key":"995_CR95","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1182\/blood-2019-130310","volume":"134","author":"N Pemmaraju","year":"2019","unstructured":"Pemmaraju N, Gundabolu K, Pettit K, Talpaz M, Podoltsev NA, Schiller GJ, et al. Phase 1b study of the epichaperome inhibitor PU-H71 administered orally with ruxolitinib continuation for the treatment of patients with myelofibrosis. Blood. 2019;134(Supplement_1):4178.","journal-title":"Blood"},{"issue":"4","key":"995_CR96","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1182\/blood.2018874560","volume":"134","author":"X Wu","year":"2019","unstructured":"Wu X, Stenson M, Abeykoon J, Nowakowski K, Zhang L, Lawson J, et al. Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma. Blood. 2019;134(4):363\u201373.","journal-title":"Blood"},{"issue":"7","key":"995_CR97","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1158\/1078-0432.CCR-18-0959","volume":"25","author":"D Yan","year":"2019","unstructured":"Yan D, Pomicter AD, Tantravahi S, Mason CC, Senina AV, Ahmann JM, et al. Nuclear-cytoplasmic transport is a therapeutic target in myelofibrosis. Clin Cancer Res. 2019;25(7):2323\u201335.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"995_CR98","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1038\/s41375-019-0379-y","volume":"33","author":"DAC Fisher","year":"2019","unstructured":"Fisher DAC, Miner CA, Engle EK, Hu H, Collins TB, Zhou A, et al. Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NF\u03baB signaling. Leukemia. 2019;33(8):1978\u201395.","journal-title":"Leukemia"},{"issue":"429","key":"995_CR99","doi-asserted-by":"publisher","first-page":"eaam7729","DOI":"10.1126\/scitranslmed.aam7729","volume":"10","author":"A Prestipino","year":"2018","unstructured":"Prestipino A, Emhardt AJ, Aumann K, O\u2019Sullivan D, Gorantla SP, Duquesne S, et al. Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Sci Transl Med. 2018;10(429):eaam7729.","journal-title":"Sci Transl Med"},{"issue":"Supplement 1","key":"995_CR100","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1182\/blood-2018-99-116474","volume":"132","author":"L Varricchio","year":"2018","unstructured":"Varricchio L, Mascarenhas J, Migliaccio AR, O\u2019Connor-McCourt M, Tremblay G, Denis J-F, et al. AVID200, a potent trap for TGF-\u03b2 ligands inhibits TGF-\u03b21 signaling in human myelofibrosis. Blood. 2018;132(Supplement 1):1791.","journal-title":"Blood"},{"issue":"Supplement_1","key":"995_CR101","doi-asserted-by":"publisher","first-page":"4201","DOI":"10.1182\/blood-2019-129017","volume":"134","author":"M Lu","year":"2019","unstructured":"Lu M, Xia L, Hoffman R. A novel combination of drugs which target both the intrinsic and extrinsic apoptotic pathways to eliminate myelofibrosis CD34+ cells. Blood. 2019;134(Supplement_1):4201.","journal-title":"Blood"},{"issue":"13 Supplement","key":"995_CR102","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1158\/1538-7445.AM2018-1874","volume":"78","author":"A Dutta","year":"2018","unstructured":"Dutta A, Nath D, Yang Y, Mohi G. Abstract 1874: The PIM kinase inhibitor TP-3654 demonstrates efficacy in a murine model of myelofibrosis. Cancer Res. 2018;78(13 Supplement):1874.","journal-title":"Cancer Res"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-020-00995-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13045-020-00995-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-020-00995-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T15:27:14Z","timestamp":1698420434000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-020-00995-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":102,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["995"],"URL":"https:\/\/doi.org\/10.1186\/s13045-020-00995-y","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"14 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"John Mascarenhas has received research funding paid to the institution from Incyte, Roche, CTI Biopharma, Novartis, Promedior, Merck, Janssen, Arog, Merus, and Pharma Essentia, Kartos, Forbius; consulting fees from Geron, Constellation, Prelude, Galecto, Promedior, and Celgene\/BMS, Kartos. Sangeetha Venugopal has nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"162"}}